Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis
To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population. PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily w...
Gespeichert in:
| Veröffentlicht in: | PloS one 2014-04, Vol.9 (4), p.e93095-e93095 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e93095 |
|---|---|
| container_issue | 4 |
| container_start_page | e93095 |
| container_title | PloS one |
| container_volume | 9 |
| creator | Huang, Chunyun Sheng, Youyu |
| description | To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population.
PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily with Jaded score ≥ 3 in pediatric patients with AD were included. The efficacy outcomes included investigator global assessment (IGA), eczema area and severity index (EASI) scores, pruritus and care giver's assessments and flares free period. Adverse events were reviewed to assess the safety.
Out of 81 studies, 7 were selected that enrolled 2,170 pediatric patients. The pooled analysis reported that pimecrolimus was no better to vehicle reducing eczema at day-8, day-26 and six weeks (OR 4.95, 95% CI 2.79-8.80), (OR 9.69, 95% CI 4.12-22.83) and (OR 3.83. 95% CI 1.94-7.56), respectively in children. Similarly, pimecrolimus did not show beneficial effects when analyzed for mild or absent pruritus at day 4 (OR 8.29, 95% CI 3.88-17.72 favoring vehicle), day 43 (OR 1.81 95% CI 1.13-2.89 favoring vehicle) and 1 week (OR 2.29, 95%CI 1.45 to 3.60 favoring vehicle) as compared with vehicle. One study comparing pimecrolimus with tacrolimus found no significant difference in achieving mild or absent pruritus (OR 0.94, 95% CI 0.44-1.99). More patients showed an improvement in overall disease in vehicle group at day 8 (OR 3.30, 95% CI 2.03-5.35), day 29 (OR 14.14, 95% CI 6.87-29.13) and day 43 (OR 4.11, 95% CI 2.59-6.52) as compared with pimecrolimus 1% group, as assessed by caregivers. No significant difference was seen between the total AEs in both groups (pimecrolimus vs vehicle/tacrolimus) (OR 1.19, 95% CI 0.85, 1.65).
The results of the present meta-analysis showed that pimecrolimus cream 1% was not significantly better to vehicle for AD in pediatrics population. |
| doi_str_mv | 10.1371/journal.pone.0093095 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1511849106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A375582655</galeid><doaj_id>oai_doaj_org_article_8301cea062404a7d91dda47ffd717dcc</doaj_id><sourcerecordid>A375582655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-c9ad72707bca3516dc847e2417fa73ab3b74b4cfebe7171d3b15a48a6b97ebd23</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEoqXwBggiIRBc7OJDHCdcIFUVh5UqFXG6tSb2ZNdVEgfbQfTt8XbTahf1AuUi0eT7__GMZ7LsKSVLyiV9e-kmP0C3HN2AS0JqTmpxLzumNWeLkhF-f-_7KHsUwiUhgldl-TA7YkVZ04IUx5n-YnvU3nW2n0KuPUKf05e5HfK4wbyHAdbY4xBz1-YQ3Wh1btD3EG20YYuNaCxEn-JjCiYyvMsh7zHCIom7q2DD4-xBC13AJ_P7JPvx8cP3s8-L84tPq7PT84UuaxYXugYjmSSy0cAFLY2uComsoLIFyaHhjSyaQrfYoKSSGt5QAUUFZVNLbAzjJ9nzne_YuaDm_gRFBaVVUVNSJmK1I4yDSzV624O_Ug6sug44v1bgo9UdqooTqhFIyVKfQJqaGgOFbFuTkhutk9f7OdvU9Gh0Kt1Dd2B6-GewG7V2vxWvJUt3kgxezwbe_ZowRNXboLHrYEA3XZ-bCSFYWSf0xT_o3dXN1BpSAXZoXcqrt6bqlEshKlYKkajlHVR6DPZWp2FqbYofCN4cCBIT8U9cwxSCWn37-v_sxc9D9tUeu0Ho4ia4borWDeEQLHZgmtMQPLa3TaZEbXfhphtquwtq3oUke7Z_Qbeim-HnfwEw_ASo</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1511849106</pqid></control><display><type>article</type><title>Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Huang, Chunyun ; Sheng, Youyu</creator><contributor>Brandner, Johanna M.</contributor><creatorcontrib>Huang, Chunyun ; Sheng, Youyu ; Brandner, Johanna M.</creatorcontrib><description>To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population.
PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily with Jaded score ≥ 3 in pediatric patients with AD were included. The efficacy outcomes included investigator global assessment (IGA), eczema area and severity index (EASI) scores, pruritus and care giver's assessments and flares free period. Adverse events were reviewed to assess the safety.
Out of 81 studies, 7 were selected that enrolled 2,170 pediatric patients. The pooled analysis reported that pimecrolimus was no better to vehicle reducing eczema at day-8, day-26 and six weeks (OR 4.95, 95% CI 2.79-8.80), (OR 9.69, 95% CI 4.12-22.83) and (OR 3.83. 95% CI 1.94-7.56), respectively in children. Similarly, pimecrolimus did not show beneficial effects when analyzed for mild or absent pruritus at day 4 (OR 8.29, 95% CI 3.88-17.72 favoring vehicle), day 43 (OR 1.81 95% CI 1.13-2.89 favoring vehicle) and 1 week (OR 2.29, 95%CI 1.45 to 3.60 favoring vehicle) as compared with vehicle. One study comparing pimecrolimus with tacrolimus found no significant difference in achieving mild or absent pruritus (OR 0.94, 95% CI 0.44-1.99). More patients showed an improvement in overall disease in vehicle group at day 8 (OR 3.30, 95% CI 2.03-5.35), day 29 (OR 14.14, 95% CI 6.87-29.13) and day 43 (OR 4.11, 95% CI 2.59-6.52) as compared with pimecrolimus 1% group, as assessed by caregivers. No significant difference was seen between the total AEs in both groups (pimecrolimus vs vehicle/tacrolimus) (OR 1.19, 95% CI 0.85, 1.65).
The results of the present meta-analysis showed that pimecrolimus cream 1% was not significantly better to vehicle for AD in pediatrics population.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0093095</identifier><identifier>PMID: 24691404</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adults ; Age ; Analysis ; Atopic dermatitis ; Care and treatment ; Children ; Clinical trials ; Cream ; Dermatitis ; Dermatology ; Drug therapy ; Eczema ; Health aspects ; Immunoglobulin A ; Immunology ; Medicine and Health Sciences ; Meta-analysis ; Patients ; Pediatrics ; Physical Sciences ; Population ; Pruritus ; Quality ; Research and Analysis Methods ; Safety ; Skin diseases ; Studies ; Tacrolimus</subject><ispartof>PloS one, 2014-04, Vol.9 (4), p.e93095-e93095</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Huang, Sheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Huang, Sheng 2014 Huang, Sheng</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-c9ad72707bca3516dc847e2417fa73ab3b74b4cfebe7171d3b15a48a6b97ebd23</citedby><cites>FETCH-LOGICAL-c692t-c9ad72707bca3516dc847e2417fa73ab3b74b4cfebe7171d3b15a48a6b97ebd23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972203/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972203/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24691404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Brandner, Johanna M.</contributor><creatorcontrib>Huang, Chunyun</creatorcontrib><creatorcontrib>Sheng, Youyu</creatorcontrib><title>Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population.
PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily with Jaded score ≥ 3 in pediatric patients with AD were included. The efficacy outcomes included investigator global assessment (IGA), eczema area and severity index (EASI) scores, pruritus and care giver's assessments and flares free period. Adverse events were reviewed to assess the safety.
Out of 81 studies, 7 were selected that enrolled 2,170 pediatric patients. The pooled analysis reported that pimecrolimus was no better to vehicle reducing eczema at day-8, day-26 and six weeks (OR 4.95, 95% CI 2.79-8.80), (OR 9.69, 95% CI 4.12-22.83) and (OR 3.83. 95% CI 1.94-7.56), respectively in children. Similarly, pimecrolimus did not show beneficial effects when analyzed for mild or absent pruritus at day 4 (OR 8.29, 95% CI 3.88-17.72 favoring vehicle), day 43 (OR 1.81 95% CI 1.13-2.89 favoring vehicle) and 1 week (OR 2.29, 95%CI 1.45 to 3.60 favoring vehicle) as compared with vehicle. One study comparing pimecrolimus with tacrolimus found no significant difference in achieving mild or absent pruritus (OR 0.94, 95% CI 0.44-1.99). More patients showed an improvement in overall disease in vehicle group at day 8 (OR 3.30, 95% CI 2.03-5.35), day 29 (OR 14.14, 95% CI 6.87-29.13) and day 43 (OR 4.11, 95% CI 2.59-6.52) as compared with pimecrolimus 1% group, as assessed by caregivers. No significant difference was seen between the total AEs in both groups (pimecrolimus vs vehicle/tacrolimus) (OR 1.19, 95% CI 0.85, 1.65).
The results of the present meta-analysis showed that pimecrolimus cream 1% was not significantly better to vehicle for AD in pediatrics population.</description><subject>Adults</subject><subject>Age</subject><subject>Analysis</subject><subject>Atopic dermatitis</subject><subject>Care and treatment</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Cream</subject><subject>Dermatitis</subject><subject>Dermatology</subject><subject>Drug therapy</subject><subject>Eczema</subject><subject>Health aspects</subject><subject>Immunoglobulin A</subject><subject>Immunology</subject><subject>Medicine and Health Sciences</subject><subject>Meta-analysis</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Physical Sciences</subject><subject>Population</subject><subject>Pruritus</subject><subject>Quality</subject><subject>Research and Analysis Methods</subject><subject>Safety</subject><subject>Skin diseases</subject><subject>Studies</subject><subject>Tacrolimus</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEoqXwBggiIRBc7OJDHCdcIFUVh5UqFXG6tSb2ZNdVEgfbQfTt8XbTahf1AuUi0eT7__GMZ7LsKSVLyiV9e-kmP0C3HN2AS0JqTmpxLzumNWeLkhF-f-_7KHsUwiUhgldl-TA7YkVZ04IUx5n-YnvU3nW2n0KuPUKf05e5HfK4wbyHAdbY4xBz1-YQ3Wh1btD3EG20YYuNaCxEn-JjCiYyvMsh7zHCIom7q2DD4-xBC13AJ_P7JPvx8cP3s8-L84tPq7PT84UuaxYXugYjmSSy0cAFLY2uComsoLIFyaHhjSyaQrfYoKSSGt5QAUUFZVNLbAzjJ9nzne_YuaDm_gRFBaVVUVNSJmK1I4yDSzV624O_Ug6sug44v1bgo9UdqooTqhFIyVKfQJqaGgOFbFuTkhutk9f7OdvU9Gh0Kt1Dd2B6-GewG7V2vxWvJUt3kgxezwbe_ZowRNXboLHrYEA3XZ-bCSFYWSf0xT_o3dXN1BpSAXZoXcqrt6bqlEshKlYKkajlHVR6DPZWp2FqbYofCN4cCBIT8U9cwxSCWn37-v_sxc9D9tUeu0Ho4ia4borWDeEQLHZgmtMQPLa3TaZEbXfhphtquwtq3oUke7Z_Qbeim-HnfwEw_ASo</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Huang, Chunyun</creator><creator>Sheng, Youyu</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140401</creationdate><title>Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis</title><author>Huang, Chunyun ; Sheng, Youyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-c9ad72707bca3516dc847e2417fa73ab3b74b4cfebe7171d3b15a48a6b97ebd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adults</topic><topic>Age</topic><topic>Analysis</topic><topic>Atopic dermatitis</topic><topic>Care and treatment</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Cream</topic><topic>Dermatitis</topic><topic>Dermatology</topic><topic>Drug therapy</topic><topic>Eczema</topic><topic>Health aspects</topic><topic>Immunoglobulin A</topic><topic>Immunology</topic><topic>Medicine and Health Sciences</topic><topic>Meta-analysis</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Physical Sciences</topic><topic>Population</topic><topic>Pruritus</topic><topic>Quality</topic><topic>Research and Analysis Methods</topic><topic>Safety</topic><topic>Skin diseases</topic><topic>Studies</topic><topic>Tacrolimus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Chunyun</creatorcontrib><creatorcontrib>Sheng, Youyu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Chunyun</au><au>Sheng, Youyu</au><au>Brandner, Johanna M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>9</volume><issue>4</issue><spage>e93095</spage><epage>e93095</epage><pages>e93095-e93095</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population.
PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily with Jaded score ≥ 3 in pediatric patients with AD were included. The efficacy outcomes included investigator global assessment (IGA), eczema area and severity index (EASI) scores, pruritus and care giver's assessments and flares free period. Adverse events were reviewed to assess the safety.
Out of 81 studies, 7 were selected that enrolled 2,170 pediatric patients. The pooled analysis reported that pimecrolimus was no better to vehicle reducing eczema at day-8, day-26 and six weeks (OR 4.95, 95% CI 2.79-8.80), (OR 9.69, 95% CI 4.12-22.83) and (OR 3.83. 95% CI 1.94-7.56), respectively in children. Similarly, pimecrolimus did not show beneficial effects when analyzed for mild or absent pruritus at day 4 (OR 8.29, 95% CI 3.88-17.72 favoring vehicle), day 43 (OR 1.81 95% CI 1.13-2.89 favoring vehicle) and 1 week (OR 2.29, 95%CI 1.45 to 3.60 favoring vehicle) as compared with vehicle. One study comparing pimecrolimus with tacrolimus found no significant difference in achieving mild or absent pruritus (OR 0.94, 95% CI 0.44-1.99). More patients showed an improvement in overall disease in vehicle group at day 8 (OR 3.30, 95% CI 2.03-5.35), day 29 (OR 14.14, 95% CI 6.87-29.13) and day 43 (OR 4.11, 95% CI 2.59-6.52) as compared with pimecrolimus 1% group, as assessed by caregivers. No significant difference was seen between the total AEs in both groups (pimecrolimus vs vehicle/tacrolimus) (OR 1.19, 95% CI 0.85, 1.65).
The results of the present meta-analysis showed that pimecrolimus cream 1% was not significantly better to vehicle for AD in pediatrics population.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>24691404</pmid><doi>10.1371/journal.pone.0093095</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2014-04, Vol.9 (4), p.e93095-e93095 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1511849106 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adults Age Analysis Atopic dermatitis Care and treatment Children Clinical trials Cream Dermatitis Dermatology Drug therapy Eczema Health aspects Immunoglobulin A Immunology Medicine and Health Sciences Meta-analysis Patients Pediatrics Physical Sciences Population Pruritus Quality Research and Analysis Methods Safety Skin diseases Studies Tacrolimus |
| title | Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A05%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pimecrolimus%20cream%201%25%20in%20the%20management%20of%20atopic%20dermatitis%20in%20pediatric%20patients:%20a%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Huang,%20Chunyun&rft.date=2014-04-01&rft.volume=9&rft.issue=4&rft.spage=e93095&rft.epage=e93095&rft.pages=e93095-e93095&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0093095&rft_dat=%3Cgale_plos_%3EA375582655%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1511849106&rft_id=info:pmid/24691404&rft_galeid=A375582655&rft_doaj_id=oai_doaj_org_article_8301cea062404a7d91dda47ffd717dcc&rfr_iscdi=true |